|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Covariates included in the models | Antiplatelets | Antiplatelets + Vitamin K inhibitors | NOACs |
| TIA or IS | Age and gender | 1.51 (1.09-2.09)p=0.014 | 1.42(0.93-2.17)p=0.102 | 1.00(0.54-1.84)p=0.997 |
|  | Age, gender, socioeconomic status and CHA2DS2VAc score. | 1.53(1.08-2.16)p=0.015 | 1.38(0.89-2.14)p=0.153 | 0.98(0.53-1.80)p=0.941 |
| CHD | Age and gender | 1.06(0.83-1.35)p=0.651 | 1.05(0.84-1.31)p=0.678 | 2.07(1.35-3.19)p=0.001 |
|  | Age, gender, socioeconomic status and CHA2DS2VAc score. | 1.05(0.81-1.35)p=0.717 | 1.06(0.84-1.32)p=0.636 | 2.15(1.34-3.44)p=0.001 |
| PAD | Age and gender | 1.26(0.68-2.36)p=0.461 | 1.33(0.67-2.64)p=0.411 | 1.82(0.68-4.82)p=0.230 |
|  | Age, gender, socioeconomic status and CHA2DS2VAc score. | 1.13(0.58-2.20)p=0.726 | 1.68(0.83-3.41)p=0.150 | 2.67(0.88-8.11)p=0.082 |
| GI haemorrhage | Age and gender | 1.79(1.01-3.18)p=0.047 | 1.46(0.74-2.91)p=0.276 | 1.56(0.63-3.85)p=0.334 |
|  | Age, gender, socioeconomic status and CHA2DS2VAc score. | 1.77(0.95-3.29)p=0.070 | 1.49(0.70-3.16)p=0.294 | 1.34(0.49-3.64)p=0.565 |

Table 2. Risk (Hazard ratio and 95% Confidence Interval) of outcomes in each treatment category compared to those who took VKAs only during the study period.